Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of BI 3923948 in Advanced Solid Tumors
NCT07395258Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Primary completion
- Jun 2031
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3923948 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-limiting toxicities at 3 weeks. Started Apr 2026; status: suspended.
02
Drugs
BI 3923948
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07395258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395258.